BRPI0508716A - anticorpo monoclonal, processo para produzir o mesmo, composição farmacêutica, e, uso de um anticorpo monoclonal - Google Patents
anticorpo monoclonal, processo para produzir o mesmo, composição farmacêutica, e, uso de um anticorpo monoclonalInfo
- Publication number
- BRPI0508716A BRPI0508716A BRPI0508716-3A BRPI0508716A BRPI0508716A BR PI0508716 A BRPI0508716 A BR PI0508716A BR PI0508716 A BRPI0508716 A BR PI0508716A BR PI0508716 A BRPI0508716 A BR PI0508716A
- Authority
- BR
- Brazil
- Prior art keywords
- monoclonal antibody
- antibodies
- producing
- pharmaceutical composition
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Obesity (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
Abstract
ANTICORPO MONOCLONAL, PROCESSO PARA PRODUZIR O MESMO, COMPOSIçãO FARMACêUTICA, E, USO DE UM ANTICORPO MONOCLONAL. Um epítopo neutralizador é identificado dentro de aminoácidos 40-46 da forma madura de miostatina de humano. Anticorpos que se ligam neste epítopo caem dentro do escopo da invenção e podem ser anticorpos murinos, quiméricos, ou humanizados, imunoconjugados dos anticorpos ou seus fragmentos ligantes de antígeno. Os anticorpos da invenção são úteis para aumentar a massa muscular, amentar a densidade óssea, ou para o tratamento de vários distúrbios em mamíferos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55545604P | 2004-03-23 | 2004-03-23 | |
US55962104P | 2004-04-05 | 2004-04-05 | |
PCT/US2005/009307 WO2005094446A2 (en) | 2004-03-23 | 2005-03-17 | Anti-myostatin antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0508716A true BRPI0508716A (pt) | 2007-08-07 |
Family
ID=35064367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0508716-3A BRPI0508716A (pt) | 2004-03-23 | 2005-03-17 | anticorpo monoclonal, processo para produzir o mesmo, composição farmacêutica, e, uso de um anticorpo monoclonal |
Country Status (14)
Country | Link |
---|---|
US (1) | US20070178095A1 (pt) |
EP (1) | EP1733041B1 (pt) |
JP (1) | JP4695133B2 (pt) |
KR (1) | KR20060133049A (pt) |
AT (1) | ATE557042T1 (pt) |
AU (1) | AU2005227896B2 (pt) |
BR (1) | BRPI0508716A (pt) |
CA (1) | CA2558805C (pt) |
EA (1) | EA014112B1 (pt) |
ES (1) | ES2384176T3 (pt) |
IL (1) | IL177956A (pt) |
MX (1) | MXPA06010929A (pt) |
NO (1) | NO20064788L (pt) |
WO (1) | WO2005094446A2 (pt) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2272864A3 (en) | 2002-12-20 | 2011-02-16 | Amgen Inc. | Binding agents which inhibit myostatin |
JP2008539241A (ja) | 2005-04-25 | 2008-11-13 | ファイザー インコーポレイティッド | ミオスタチンに対する抗体 |
KR101135220B1 (ko) * | 2005-10-06 | 2012-04-24 | 일라이 릴리 앤드 캄파니 | 항-마이오스타틴 항체 |
UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
CA2856436A1 (en) * | 2005-12-06 | 2007-06-14 | Amgen Inc. | Uses of myostatin antagonists |
JP5624276B2 (ja) | 2006-03-31 | 2014-11-12 | 中外製薬株式会社 | 抗体の血中動態を制御する方法 |
WO2008030706A2 (en) * | 2006-09-05 | 2008-03-13 | Eli Lilly And Company | Anti-myostatin antibodies |
US8501713B2 (en) | 2007-08-03 | 2013-08-06 | Summit Corporation Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
JP5334319B2 (ja) | 2007-09-26 | 2013-11-06 | 中外製薬株式会社 | Cdrのアミノ酸置換により抗体の等電点を改変する方法 |
PE20091163A1 (es) * | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
KR20220162801A (ko) | 2008-04-11 | 2022-12-08 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
WO2010002862A2 (en) * | 2008-07-01 | 2010-01-07 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (fgfr3) binding proteins |
HUP0800448A2 (en) * | 2008-07-21 | 2011-02-28 | Pecsi Tudomanyegyetem | Diagnosis of systemic diseases |
TW201029662A (en) | 2008-12-19 | 2010-08-16 | Glaxo Group Ltd | Novel antigen binding proteins |
FR2943249B1 (fr) * | 2009-03-18 | 2011-08-12 | Genethon | Utilisation de la decorine pour augmenter la masse musculaire |
JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
UY33421A (es) | 2010-06-03 | 2011-12-30 | Glaxo Wellcome House | Proteinas de union al antígeno humanizados |
EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
LT2780368T (lt) | 2011-11-14 | 2018-03-12 | Regeneron Pharmaceuticals, Inc. | Kompozicijos ir būdai raumenų masės padidinimui ir raumenų sustiprinimui, specifiškai antagonizuojant gdf8 ir (arba) aktiviną a |
FR2982860B1 (fr) | 2011-11-18 | 2015-07-10 | Ass Fr Contre Les Myopathies | Utilisation de la fibromoduline et du lumican pour augmenter la masse musculaire |
CN104507967B (zh) * | 2012-01-20 | 2018-10-12 | 建新公司 | 抗cxcr3抗体 |
KR101704893B1 (ko) * | 2012-06-15 | 2017-02-08 | 화이자 인코포레이티드 | Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도 |
EP3711771A1 (en) | 2012-08-01 | 2020-09-23 | Ikaika Therapeutics, LLC | Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4) |
US11236168B2 (en) | 2012-08-24 | 2022-02-01 | Chugai Seiyaku Kabushiki Kaisha | Mouse FcγammaRII-specific Fc antibody |
BR112015001955A2 (pt) | 2012-08-24 | 2017-11-07 | Chugai Pharmaceutical Co Ltd | variante de região fc específica de fcgamariib |
US8933199B2 (en) | 2012-09-13 | 2015-01-13 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind to myostatin |
WO2014163101A1 (ja) | 2013-04-02 | 2014-10-09 | 中外製薬株式会社 | Fc領域改変体 |
EP4140497A1 (en) | 2013-04-08 | 2023-03-01 | President and Fellows of Harvard College | Compositions for rejuvenating skeletal muscle stem cells |
EP3816625A1 (en) | 2013-05-06 | 2021-05-05 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
US20160220640A1 (en) * | 2013-06-11 | 2016-08-04 | The Brigham And Women's Hospital, Inc. | Methods and compositions for increasing neurogenesis and angiogenesis |
TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素a之抗體及其用途 |
JP2017518958A (ja) * | 2014-03-19 | 2017-07-13 | マッカイ メディカル ファウンデイション ザ プレスビテリアン チャーチ イン タイワン マッカイ メモリアル ホスピタルMackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital | 免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用 |
EP3215175A4 (en) | 2014-11-06 | 2018-06-27 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
KR20180054923A (ko) | 2014-12-19 | 2018-05-24 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
MX2017008978A (es) | 2015-02-05 | 2017-10-25 | Chugai Pharmaceutical Co Ltd | Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos. |
EA201792298A1 (ru) | 2015-04-15 | 2018-04-30 | Регенерон Фармасьютикалз, Инк. | Способы увеличения силы и функциональности с помощью ингибиторов gdf8 |
US11359009B2 (en) * | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
JP6948331B2 (ja) | 2016-01-06 | 2021-10-13 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する |
CN116059346A (zh) | 2016-06-17 | 2023-05-05 | 中外制药株式会社 | 抗-肌肉生长抑制因子抗体及使用方法 |
US11053308B2 (en) | 2016-08-05 | 2021-07-06 | Chugai Seiyaku Kabushiki Kaisha | Method for treating IL-8-related diseases |
AU2018205270B2 (en) * | 2017-01-06 | 2022-08-11 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
KR20200128125A (ko) | 2018-03-01 | 2020-11-11 | 리제너론 파아마슈티컬스, 인크. | 신체 조성을 변경하기 위한 방법 |
EP3898672A1 (en) | 2018-12-18 | 2021-10-27 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, gdf8 and activin a |
US20220143136A1 (en) | 2018-12-21 | 2022-05-12 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
US20220062299A1 (en) | 2018-12-26 | 2022-03-03 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
WO2024064842A1 (en) | 2022-09-21 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5994618A (en) * | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
ES2201076T3 (es) * | 1993-03-19 | 2004-03-16 | The Johns Hopkins University School Of Medicine | Factor-8 de diferenciacion del crecimiento. |
US20030074680A1 (en) * | 1993-03-19 | 2003-04-17 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
KR100259828B1 (ko) * | 1995-09-11 | 2000-06-15 | 히라타 다다시 | 인체 인터루킨 5 수용체 알파-사슬에 대한 항체 |
US6103466A (en) * | 1997-07-14 | 2000-08-15 | University Of Liege | Double-muscling in mammals |
US6696260B1 (en) * | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
GB2333706A (en) * | 1998-02-02 | 1999-08-04 | Merck & Co Inc | Method for increasing muscle mass in animals |
ES2330062T3 (es) * | 1998-05-06 | 2009-12-03 | Metamorphix, Inc. | Procedimientos para tratar la diabetes por inhibicion de gdf-8. |
US6537781B1 (en) * | 1999-08-10 | 2003-03-25 | Idexx Laboratories, Inc. | Methods and compositions concerning canine interleukin 5 |
US7320789B2 (en) * | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
-
2005
- 2005-03-17 JP JP2007505055A patent/JP4695133B2/ja not_active Expired - Fee Related
- 2005-03-17 KR KR1020067021903A patent/KR20060133049A/ko not_active Application Discontinuation
- 2005-03-17 EP EP05734951A patent/EP1733041B1/en not_active Revoked
- 2005-03-17 BR BRPI0508716-3A patent/BRPI0508716A/pt not_active IP Right Cessation
- 2005-03-17 AU AU2005227896A patent/AU2005227896B2/en not_active Ceased
- 2005-03-17 WO PCT/US2005/009307 patent/WO2005094446A2/en active Application Filing
- 2005-03-17 MX MXPA06010929A patent/MXPA06010929A/es active IP Right Grant
- 2005-03-17 CA CA2558805A patent/CA2558805C/en not_active Expired - Fee Related
- 2005-03-17 US US10/593,810 patent/US20070178095A1/en not_active Abandoned
- 2005-03-17 EA EA200601752A patent/EA014112B1/ru not_active IP Right Cessation
- 2005-03-17 ES ES05734951T patent/ES2384176T3/es active Active
- 2005-03-17 AT AT05734951T patent/ATE557042T1/de active
-
2006
- 2006-09-07 IL IL177956A patent/IL177956A/en not_active IP Right Cessation
- 2006-10-23 NO NO20064788A patent/NO20064788L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP4695133B2 (ja) | 2011-06-08 |
ES2384176T3 (es) | 2012-07-02 |
EA200601752A1 (ru) | 2007-02-27 |
JP2007530551A (ja) | 2007-11-01 |
IL177956A (en) | 2010-11-30 |
AU2005227896A1 (en) | 2005-10-13 |
EA014112B1 (ru) | 2010-10-29 |
AU2005227896B2 (en) | 2008-11-13 |
NO20064788L (no) | 2006-12-05 |
MXPA06010929A (es) | 2007-01-16 |
EP1733041B1 (en) | 2012-05-09 |
ATE557042T1 (de) | 2012-05-15 |
US20070178095A1 (en) | 2007-08-02 |
IL177956A0 (en) | 2006-12-31 |
WO2005094446A2 (en) | 2005-10-13 |
CA2558805A1 (en) | 2005-10-13 |
KR20060133049A (ko) | 2006-12-22 |
EP1733041A4 (en) | 2009-01-28 |
WO2005094446A3 (en) | 2005-12-22 |
EP1733041A2 (en) | 2006-12-20 |
CA2558805C (en) | 2011-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0508716A (pt) | anticorpo monoclonal, processo para produzir o mesmo, composição farmacêutica, e, uso de um anticorpo monoclonal | |
UA92504C2 (en) | Anti-myostatin monoclonal antibody | |
WO2007044411A3 (en) | Anti-myostatin antibodies | |
PL374587A1 (en) | Pharmaceutical compositions directed to erb-b1 receptors | |
MX2019013132A (es) | Anticuerpos que comprenden regiones constantes pesadas modificadas. | |
PE20090689A1 (es) | Anticuerpos del antagonista ox40 y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
TW200738748A (en) | Human monoclonal antibody human CD134 (OX40) and methods of making and using same | |
ECSP078026A (es) | Anticuerpos anti-cd40 humanizados y sus métodos de uso | |
CY1112277T1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
WO2006138729A3 (en) | Receptor antagonists for treatment of metastatic bone cancer | |
RU2430111C3 (ru) | Молекулы антител с улучшенными свойствами | |
BRPI0418695A (pt) | uso terapêutico de anticorpos anti-cs1 | |
CY1113224T1 (el) | Νεο αντισωμα αντι-ρlgf | |
AR072985A1 (es) | Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union | |
WO2006121852A3 (en) | Anti-cd19 antibody therapy for autoimmune disease | |
UA89350C2 (uk) | Гуманізоване антитіло, що зв'язує людський cd20 | |
WO2021203030A3 (en) | Methods of use of anti-trem2 antibodies | |
MX2021015212A (es) | Anticuerpos antisortilina para uso en terapia. | |
EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
WO2003073982A3 (en) | Anti-interleukin-1 beta analogs | |
AR046094A1 (es) | Anticuerpos completamente humanos contra 4-1bb humano | |
DK1411962T3 (da) | Terapi for pancreacancer med monoklonalt stof | |
EA202092595A1 (ru) | Антитела к siglec-7 и способы их применения | |
WO2008042941A3 (en) | Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease | |
BR112022011122A2 (pt) | Epítopos e anticorpos de trpv1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014. |